A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)

Objective: To determine the safety, pharmacokinetics, tolerance, antiretrov iral activity, and infant HIV infection status after giving a single dose o f nevirapine to HIV-1-infected pregnant women during labor and their newbor ns during the first week of life. Design: An open label phase I/II study. Setting: Tertiary care hospital, Kampala, Uganda. Patients and interventions: Nevirapine, 200 mg, was given as a single dose during labor to 21 HIV-1-infected pregnant Ugandan women. In cohort 1, eigh t infants did not receive nevirapine whereas in cohort 2, 13 infants receiv ed a single dose of nevirapine, 2 mg/kg, at 72 h of age. Outcomes: The number and type of adverse events; nevirapine concentrations in the plasma and breast milk; maternal plasma HIV-1 RNA copy number before and up to 6 weeks after delivery and HIV-1 infection status of the infants were monitored. Results: Nevirapine was well tolerated by women and infants; no serious adv erse events that were related to nevirapine were observed. Median nevirapin e concentration in the women at delivery was 1623 ng/ml (range 238-2356 ng/ ml); median cord/maternal blood ratio of 0.75 (0.37-0.93). The median half- life in women was 61.3 h (27-90 h) and the transplacental nevirapine half-l ife in infants who did not receive a neonatal dose was 54 h. The median hal f-life after a single dose at 72 h in infants was 46.5 h. During the first week of life, the median colostrum/breast milk to maternal plasma nevirapin e concentration was 60.5% (25-122%). The median nevirapine concentration in breast milk 1 week after delivery was 103 ng/ml (25-309 ng/ml). Plasma nev irapine concentrations were above 100 ng/ml in all infants from both cohort s tested at age 7 days. Maternal HIV-1 RNA levels decreased by a median of 1.3 logs at 1 week postpartum, and returned to baseline by 6 weeks postpart um. Detectable plasma HIV-1 RNA was observed in one out of 22 (4.5%) infant s at birth; three out of 21 (14%) at 6 weeks; and four out of 21 (19%) at 6 months of age. Conclusion: The administration of a single dose of nevirapine to women duri ng labor and to their newborns at 72 h was well tolerated and showed potent antiretroviral activity in the women at 1 week after dosing without reboun d above baseline 6 weeks after a single dose. The nevirapine concentration was maintained above the target of 100 ng/ml in infants at age 7 days, even in those infants not receiving a neonatal dose. This regimen has promise a s prophylaxis against intrapartum and early breast milk transmission in a b reastfeeding population. (C) 1999 Lippincott Williams & Wilkins.